GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Cyclically Adjusted PB Ratio

Nymox Pharmaceutical (Nymox Pharmaceutical) Cyclically Adjusted PB Ratio : (As of May. 15, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nymox Pharmaceutical Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Nymox Pharmaceutical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Cyclically Adjusted PB Ratio Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nymox Pharmaceutical's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Nymox Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Cyclically Adjusted PB Ratio falls into.



Nymox Pharmaceutical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Nymox Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Nymox Pharmaceutical's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.02/129.8595*129.8595
=-0.020

Current CPI (Sep. 2023) = 129.8595.

Nymox Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201312 -0.186 98.326 -0.246
201403 -0.190 99.695 -0.247
201406 -0.175 100.560 -0.226
201409 -0.140 100.428 -0.181
201412 -0.128 99.070 -0.168
201503 -0.076 99.621 -0.099
201506 -0.061 100.684 -0.079
201509 -0.084 100.392 -0.109
201512 -0.055 99.792 -0.072
201603 -0.042 100.470 -0.054
201606 -0.056 101.688 -0.072
201609 -0.038 101.861 -0.048
201612 -0.005 101.863 -0.006
201703 -0.023 102.862 -0.029
201706 -0.014 103.349 -0.018
201709 0.000 104.136 0.000
201712 -0.022 104.011 -0.027
201803 -0.018 105.290 -0.022
201806 0.058 106.317 0.071
201809 0.063 106.507 0.077
201812 0.108 105.998 0.132
201903 0.149 107.251 0.180
201906 0.109 108.070 0.131
201909 0.080 108.329 0.096
201912 0.048 108.420 0.057
202003 0.020 108.902 0.024
202006 -0.015 108.767 -0.018
202009 0.050 109.815 0.059
202012 0.028 109.897 0.033
202103 0.000 111.754 0.000
202106 0.056 114.631 0.063
202109 0.019 115.734 0.021
202112 -0.006 117.630 -0.007
202203 -0.015 121.301 -0.016
202206 0.024 125.017 0.025
202209 0.008 125.227 0.008
202212 -0.005 125.222 -0.005
202303 -0.020 127.348 -0.020
202306 -0.032 128.729 -0.032
202309 -0.020 129.860 -0.020

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nymox Pharmaceutical  (OTCPK:NYMXF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Nymox Pharmaceutical Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-02-2022

NYMOX Receives RTF letter from FDA

By PurpleRose PurpleRose 07-12-2022

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 05-23-2022

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GuruFocusNews GuruFocusNews 11-15-2021

Nymox Announces $5 Million Registered Direct Offering

By GuruFocusNews GuruFocusNews 03-18-2022

May 2023 Market Cap Requirement Update

By Value_Insider Value_Insider 11-25-2022

Nymox Announces Closing of $6.4 Million Financing

By GuruFocusNews GuruFocusNews 04-04-2022

NYMOX Updates Shareholders

By PurpleRose PurpleRose 07-15-2022